Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M229,499Revenue $M53,619Net Margin (%)18.7Z-Score3.7
Enterprise Value $M231,593EPS $1.5Operating Margin %28.3F-Score5
P/E(ttm))24.1Cash Flow Per Share $0Pre-tax Margin (%)25.1Higher ROA y-yN
Price/Book10.310-y EBITDA Growth Rate %4.7Quick Ratio1.0Cash flow > EarningsY
Price/Sales4.55-y EBITDA Growth Rate %3.8Current Ratio1.4Lower Leverage y-yN
Price/Cash Flow0y-y EBITDA Growth Rate %-14.0ROA % (ttm)14.0Higher Current Ratio y-yN
Dividend Yield %3.3Insider Buy (3m)0ROE % (ttm)45.0Less Shares Outstanding y-yY
Payout Ratio %73.0Shares Outstanding M6,798ROI % (ttm)33.6Gross Margin Increase y-yN

Gurus Latest Trades with RHHBY

Number of guru portfolios checked: 85. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
RHHBYKen Fisher 2014-12-31 Add0.07%$34.16 - $37.92
($36.33)
$ 34.13-6%Add 49.26%2,823,025
RHHBYKen Fisher 2014-06-30 Reduce-0.07%$35.42 - $38.07
($36.82)
$ 34.13-7%Reduce -49.71%1,813,443
RHHBYKen Fisher 2014-03-31 Add0.07%$18.14 - $38.17
($29.75)
$ 34.1315%Add 99%1,803,070
RHHBYTweedy Browne 2013-06-30 Sold Out $28.92 - $32.98
($30.92)
$ 34.1310%Sold Out0
RHHBYKen Fisher 2013-03-31 Add0.12%$25.25 - $29.3
($27.74)
$ 34.1323%Add 634.57%897,861
RHHBYTweedy Browne 2012-09-30 Reduce-0.03%$20.95 - $24.07
($22.41)
$ 34.1352%Reduce -24.31%62,164
RHHBYVanguard Health Care Fund 2012-06-30 Add2.96%$19.47 - $23.14
($21.16)
$ 34.1361%Add 543.36%4,273,977
RHHBYKen Fisher 2012-06-30 Reduce-0.01%$19.47 - $23.14
($21.16)
$ 34.1361%Reduce -24.26%154,713
RHHBYKen Fisher 2012-03-31 Reduce-1.27%$21.55 - $22.17
($20.04)
$ 34.1370%Reduce -98.02%204,276
RHHBYTweedy Browne 2012-03-31 Reduce-0.04%$21.55 - $22.17
($20.04)
$ 34.1370%Reduce -22.19%82,130
RHHBYKen Fisher 2009-03-31 Add1.01%$13.37 - $18.53
($15.95)
$ 34.13114%Add 96.11%12,225,393
RHHBYVanguard Health Care Fund 2009-03-31 Reduce-0.2%$13.37 - $18.53
($15.95)
$ 34.13114%Reduce -52.1%429,320
RHHBYVanguard Health Care Fund 2008-12-31 Add2.01%$31.33 - $38.5
($35.55)
$ 34.13-4%Add 95.76%5,113,297
RHHBYPRIMECAP Management 2008-12-31 Sold Out -1.2%$31.33 - $38.5
($35.55)
$ 34.13-4%Sold Out0
RHHBYKen Fisher 2008-12-31 Reduce-1.15%$8.06 - $19.92
($17.52)
$ 34.1395%Reduce -56.79%6,233,841
RHHBYPRIMECAP Management 2008-09-30 Buy 1.2%$20.05 - $22.89
($21.5)
$ 34.1359%New holding, 4306500 sh.4,306,500
RHHBYKen Fisher 2008-06-30 Add1.14%$19.95 - $23.69
($21.4)
$ 34.1360%Add 223.59%7,046,449
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

RHHBY is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
RHHBY Ken Fisher 2014-12-312,823,0250.040.2+49.26%
Premium Most recent portfolio changes are included for Premium Members only!


RHHBY: Insider Buys/Sells

Click Here for All Insider Trades.

No Insider Trades Found!

Press Releases about RHHBY :

    Quarterly/Annual Reports about RHHBY:

      News about RHHBY:

      Articles On GuruFocus.com
      Can These Three BioTech Companies Make It Big? Feb 20 2015 
      Pharmaceuticals Sector To See High Voltage Action in 2015 Jan 23 2015 
      Roche In Expansion Mode Jan 19 2015 
      Why Organovo is A Safe Buy? Dec 18 2014 
      Is Organovo A Safe Buy? Dec 08 2014 
      The Top 5 European Stocks Held During Q3 Nov 25 2014 
      Tweedy Browne Global Reports its Top Five Picks of Q3 Oct 21 2014 
      Widely Held Guru Stocks Trading In Europe Sep 22 2014 
      Dodge & Cox Second Quarter 2014 Commentary Jul 23 2014 
      Tweedy Browne Global Reports Their Second Quarter Portfolio Jul 18 2014 


      More From Other Websites
      Will Exelixis (EXEL) Miss Estimates this Earnings Season? - Analyst Blog Feb 23 2015
      A 'Great Entry Point' for AbbVie; Pfizer a 'Value Creation Machine' Feb 20 2015
      Regeneron's Eylea Tops Diabetic Macular Edema Study - Analyst Blog Feb 19 2015
      Update: Regeneron: Too Much Excitement About Eylea News? Feb 19 2015
      FDA Grants Genentech’s Cobimetinib Priority Review for Use in Combination with Zelboraf... Feb 19 2015
      The Sham Of Drug Testing For Benefits: Walker, Scott And Political Pandering Feb 17 2015
      ROCHE HOLDING LTD /FI Financials Feb 12 2015
      Pfenex Inc. In Development Pact For Macular Degeneration Drug Feb 10 2015
      Roche's Lucentis Gets FDA Nod for Diabetic Retinopathy - Analyst Blog Feb 09 2015
      Glaxo Submits Another Revolade Application in the EU - Analyst Blog Feb 09 2015
      Tetraphase Fights Drug-Resistant Bugs As M&A Heats Up Feb 09 2015
      Roche acquires Signature Diagnostics to advance translational research for next generation... Feb 09 2015
      FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) for Treatment of Diabetic Retinopathy... Feb 06 2015
      Roche Holding AG (RHHBY): New Analyst Report from Zacks Equity Research - Zacks Equity Research... Feb 06 2015
      Roche Reports Positive Data on Leukemia Drug Gazyva - Analyst Blog Feb 05 2015
      Exelixis Data Release Upcoming; Options Activity Spiking Feb 05 2015
      Amgen Reveals Positive Results on Biosimilar Candidate - Analyst Blog Feb 04 2015
      Genentech’s Phase III Study of Gazyva® Showed Significant Benefit in Refractory Indolent... Feb 04 2015
      Roche's Anti-PDL1 Gets Breakthrough Status for Lung Cancer - Analyst Blog Feb 03 2015
      Data Snapshot: VC-Backed BioPharma M&A 2014 Feb 03 2015

      Add Notes, Comments

      If you want to ask a question, or report a bug, please create a support ticket.

      User Comments

      Steve.dunfield@google
      ReplySteve.dunfield@google - 11 months ago
      Adjust for split?
      Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
      GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
      Free 7-day Trial
      FEEDBACK